rence, and the XIV International Congress of Dermatology (ICD). In addition, Galderma announced the initiation of two new clinical trials evaluating nemolizumab in Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO), with the first patient enrolled in the CPUO trial in December 2025.

As well as presenting new Relfydess data throughout the year, Galderma unveiled final nine-month data from a phase IV first-of-its-kind trial showing lasting efficacy and patient satisfaction with Restylane Lyft or Contour®in combination with Sculptra when addressing facial aesthetic changes following medication-driven weight loss. This work supported the development of international consensusbased guidelines.

Galderma also had a strong presene at additional major medical congresses, including the IMCAS World Congress 2025, the Aesthetic & Anti-Aging Medicine World Congress (AMWC) Monaco, AMWC Dubai, and the American Society for Dermatologic Surgery (ASDS) 202
=*=*=*=*=*=
当前为第16/55页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页